George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
Yep, pretty much steady as she goes! Still a decent dividend and cautious optimism for the future, so looks like I’ll stick around a while longer!
An interesting finish to the day FB! At this rate I might join you with an additional purchase. A share which has done nothing for so long - apart from decline! yet still produces a decent divi, has attracted consistent chunky purchases over the past days.
Yep me too. Wierd. I haven’t given up completely that something might be coming, before it retraces!
Another dart in the board this morning; not a bullseye by any stretch, but Frost&Sullivan are one of the world leaders in industry research and big industry often uses their expertise to assist in strategy formulation. This award will get noticed.
This is very positive news Smart. I wonder how long they plan on being on-board for? If they‘ve invested the bulk of the £10M, I Wonder how many multiples thereof do they expect to see that turn into, and within what timeframe.
Good idea WB. I took up the offer, so I’m happy to have a bit more flesh on the bones on the £10.5M strategic investment direction, for example the expected payback period on that. The big contributors presumably have the inside track on that - so unless there is proprietary customer 1st mover stuff curtailing wider dissemination, It would be nice to know! Let us know how you get on.
Well done FB I’m sitting on the fence, something definitely on the cards - hoping for something substantial versus a SP manipulation.
“Beyond market expectations”
I am part of the market with my small (significant for me) shareholding and my expectation (or hope!) for 2022 was $7M. I really believe we are on the cusp of something but by way of criticism of the management team, they can’t always harp on about TAM’s and SAM’s in the BILLIONS in the markets they are going after (correctly in my view) withou relativising (if that’s a word) that with a bit more specificity on their profitable growth plans. Which, to be fair, I guess they are trying the do with the Finncap notes. JS is conservative by nature, but c’mon John, drop a bombshell, rocket when the time is right!
Another thought on this: the RNS & Broker note mentions $1.9M OPex/Capex for 2023 and $3.6M Capex (no OPex) for 2024. An Interesting distinction, where the OPex part this year, to me, may well mean people Investment to run new plant capacity (Capex), wherever that may be.
If that’s the case, Co-locating onto a strategic customer/supplier site has merit. I remember John saying a future vision would be a strategic location in Europe for producing Itaconic Acid. Maybe the capital spend is to vertically integrate…
Exciting times ahead.
Well, that covered a lot of bases. A 3.6M capital spend sounds intriguing. I remember JS saying in previous presentations saying to expand existing facilities is relatively low cost Capex (ca. 0.5M?) so this sounds more substantial. Maybe a capital investment in a JV manufacturing partner. Time will tell. Either way it is very encouraging the management team is looking way down the tracks and can see what is coming. Good also that the contingent consideration is out of the way, with Yvon Durant getting shy of 2M shares. JS and his team can now really concentrate on rolling out (hopefully!) lots of good news. BIoAsterix, superabsorbents, coatings inter alia.
Fair point Surfie. None of us have a crystal ball and stuff can & does happen with risks that sometimes come home to roost. If we were beyond break even - which has been a long time coming - I’d be a tad happier. I’ve not given up yet though on my 20p by (end of) ‘23. Hoping this year’s RNS’s march us towards that.
Hi all, at (slightly nervous!) times like this sometimes we need a reminder of what we actually have (I know I do) to help keep the faith; so here is one: an excerpt from a Nouryon Press Release in 2019 - not that long ago:
“The new range of polymers strengthens Nouryon’s position as a leader in the chelates industry,” Kuijpers said. “Establishing this unique position is of strategic importance and underlines our commitment to sustainable growth.”
Peter Nieuwenhuizen, Chief Technology Officer at Nouryon, added: “We are pleased to complete the first supply agreement under our collaboration with Itaconix around its novel itaconic acid polymer platform. We firmly believe in the power and potential of collaborative innovation. By partnering, we create even greater innovation opportunities to offer to our customers.”
John R. Shaw, CEO of Itaconix, said: “I am excited that our joint work with Nouryon over the last year has created this global opportunity for our polymers.”
Peter Nieuwenhuizen is now our chair.
Every single box is ticked for me AJP - apart from one:
The box which says:
Profitable Revenue Growth Curve Back on Track.
C‘mon Itaconix, it‘s no longer if but when.
Maybe we LTH’s should all offer ourselves as free commission only sales champions!
Slainte